236 related articles for article (PubMed ID: 34114922)
1. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
Komrokji R; Al Ali N; Padron E; Lancet J; Nazha A; Steensma D; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Sallman D
Leuk Lymphoma; 2021 Nov; 62(11):2762-2767. PubMed ID: 34114922
[TBL] [Abstract][Full Text] [Related]
2. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Zeidan AM; Salimi T; Epstein RS
Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
[TBL] [Abstract][Full Text] [Related]
3. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.
Zeidan AM; Klink AJ; McGuire M; Feinberg B
Leuk Lymphoma; 2019 Aug; 60(8):2050-2055. PubMed ID: 30636526
[TBL] [Abstract][Full Text] [Related]
4. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
[TBL] [Abstract][Full Text] [Related]
5. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
[TBL] [Abstract][Full Text] [Related]
6. Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes.
Cheng WY; Satija A; Cheung HC; Hill K; Wert T; Laliberté F; Lefebvre P
Hematology; 2021 Dec; 26(1):261-270. PubMed ID: 33631084
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
Madanat Y; Sekeres MA
Semin Hematol; 2017 Jul; 54(3):147-153. PubMed ID: 28958288
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Bewersdorf JP; Zeidan AM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
[TBL] [Abstract][Full Text] [Related]
9. Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment.
Zeidan AM; Jayade S; Schmier J; Botteman M; Hassan A; Ruiters D; Hill K; Joshi N
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e185-e198. PubMed ID: 34674983
[TBL] [Abstract][Full Text] [Related]
10. When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?
Sohn SK; Moon JH
Expert Rev Hematol; 2013 Aug; 6(4):389-95. PubMed ID: 23991925
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylating agent based combinations in higher risk myelodysplastic syndrome.
Chandhok NS; Lewis R; Prebet T
Leuk Lymphoma; 2020 May; 61(5):1012-1027. PubMed ID: 31814484
[TBL] [Abstract][Full Text] [Related]
12. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents.
Zeidan AM; Hu X; Zhu W; Stahl M; Wang R; Huntington SF; Giri S; Bewersdorf JP; Podoltsev NA; Gore SD; Ma X; Davidoff AJ
Leuk Lymphoma; 2020 Feb; 61(2):397-408. PubMed ID: 31570040
[TBL] [Abstract][Full Text] [Related]
13. Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes.
Kim Y; Kim IH; Kim HJ; Park S; Lee KH; Kim SJ; Lee JH; Kim DY; Yoon SS; Kim YK; Jang JH; Park SY; Ahn JS; Cheong CW; Lee JH; Cheong JW;
Int J Hematol; 2014; 99(5):635-43. PubMed ID: 24648120
[TBL] [Abstract][Full Text] [Related]
14. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
[TBL] [Abstract][Full Text] [Related]
15. The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.
Cogle CR; Kurtin SE; Bentley TG; Broder MS; Chang E; Megaffin S; Fruchtman S; Petrone ME; Mukherjee S
Oncologist; 2017 Apr; 22(4):379-385. PubMed ID: 28283585
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Azizi A; Ediriwickrema A; Dutta R; Patel SA; Shomali W; Medeiros B; Iberri D; Gotlib J; Mannis G; Greenberg P; Majeti R; Zhang T
Leuk Lymphoma; 2020 Nov; 61(11):2700-2707. PubMed ID: 32543932
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Stein EM; Bonifacio G; Latremouille-Viau D; Shi S; Guerin A; Wu EQ; Sadek I; Cao X
Leuk Lymphoma; 2021 Jun; 62(6):1411-1421. PubMed ID: 33430673
[TBL] [Abstract][Full Text] [Related]
19. Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
Komrokji RS
Am Soc Clin Oncol Educ Book; 2016; 35():e345-52. PubMed ID: 27249741
[TBL] [Abstract][Full Text] [Related]
20. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]